**Author details**

Yanisa Rattanapan1 and Takol Chareonsirisuthigul<sup>2</sup> \*

1 School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand

2 Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

\*Address all correspondence to: toptakol@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**59**

17320505.

*Epigenetic Events in Ovarian Cancer*

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/

[2] Cannistra SA. Cancer of the ovary [published correction appears in N Engl J Med. 2005 Jan 6;352(1):104]. N Engl J Med. 2004;351(24):2519-2529.

[3] Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107(8):1711-

[4] Ramus SJ, Harrington PA, Pye C, et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat. 2007;28(12):1207-

doi:10.1056/NEJMra041842

1742. doi:10.1002/cncr.22193

1215. doi:10.1002/humu.20599

[5] Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236. doi:10.3322/

[6] Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-692.

[7] Lopez J, Percharde M, Coley HM, Webb A, Crook T. The context and potential of epigenetics in oncology. Br J Cancer. 2009;100(4):571-577.

Lander ES. The mammalian epigenome. Cell. 2007 Feb 23;128(4):669-81. doi: 10.1016/j.cell.2007.01.033. PMID:

[9] Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159.

doi:10.1016/j.cell.2007.01.029

doi:10.1038/sj.bjc.6604930

[8] Bernstein BE, Meissner A,

doi:10.1056/NEJMra072067

caac.20121

**References**

caac.21590

*DOI: http://dx.doi.org/10.5772/intechopen.95472*

[10] Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;15(17(10)):630-41.

[11] Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics. 2015;7:127. Published 2015 Dec 10. doi:10.1186/

[12] Ahluwalia A, Yan P, Hurteau JA, et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol. 2001;82(2):261-268. doi:10.1006/

[13] Ibanez de Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64(18):6476-6481. doi:10.1158/0008-5472.CAN-04-1529

[14] Rattanapan Y, Korkiatsakul V, Kongruang A, et al. EGFL7 and

cancergen.2018.04.117

hmg/ddt160

RASSF1 promoter hypermethylation in epithelial ovarian cancer. Cancer Genet. 2018;224-225:37-40. doi:10.1016/j.

[15] Cicek MS, Koestler DC, Fridley BL, et al. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum Mol Genet. 2013;22(15):3038-3047. doi:10.1093/

[16] Shen H, Fridley BL, Song H, et al. Epigenetic analysis leads to identification of HNF1B as a subtypespecific susceptibility gene for ovarian cancer. Nat Commun. 2013;4:1628.

doi:10.1038/ncomms2629

s13148-015-0157-2

gyno.2001.6291
